CXCR4 and lymphoma: The first description of CXCR4 targeting in patients with lymphoma was offered by Wester et al. in a proof-of-concept study that aimed at demonstrating the potential of [68Ga]pentixaforiPET for in-vivo quantification of CXCR4 expression for subsequent treatment strategies [16].